AstellasAstellas Pharma Inc.4503東証プライム医薬品FY ending Mar 2024, consolidated, IFRS

Astellas FY ending Mar 2023 results

Astellas brought in ¥1.52T in revenue.

Revenue changed +17.2% from the prior year.

What changed from last year

FY ending Mar 2022 → FY ending Mar 2023

FY ending Mar 2022 → FY ending Mar 2023

※ Cost of revenue is not disclosed; expenses are combined

※ Operating income is not disclosed; the chart goes straight to pretax income including investment gains

A machine-readable operating income value exists, but it is not in the validated published data, so the chart is omitted.

Show source documents (4)

EDINET (FSA Japan)
有価証券報告書－第21期(2025/04/01－2026/03/31)
ID S100YBPK2026-06-16Open
EDINET (FSA Japan)
訂正有価証券報告書－第18期(2022/04/01－2023/03/31)
ID S100SMI32024-01-16Open
EDINET (FSA Japan)
有価証券報告書－第17期(令和3年4月1日－令和4年3月31日)
ID S100O9T72022-06-20Open
EDINET (FSA Japan)
有価証券報告書－第16期(令和2年4月1日－令和3年3月31日)
ID S100LIQN2021-06-18Open

Extracted from XBRL: 9 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.